News | March 25, 2010

Study Evaluates Use of Cardiac Plug to Close the Left Atrial Appendage

March 25, 2010 – The FDA this week granted permission for a conditional investigational device exemption (IDE) to evaluate the safety and efficacy of a transcatheter plug to seal the left atrial appendage (LAA). The appendage is frequently the source of stroke-causing clots in atrial fibrillation patients.

The study will evaluate the Amplatzer Cardiac Plug, or ACP. The trial is designed to demonstrate efficacy in preventing stroke in atrial fibrillation patients who are eligible to receive warfarin, as well as safety of the device and the procedure.

The ACP clinical study will be a multicenter trial with a two-to-one randomization between the ACP and medical management, warfarin, the current standard of care. The study design is based on a statistical method referred to as a Bayesian adaptive design with interim analyses that use observed efficacy and safety event rate data to predict the final sample size, probabilities for trial success and when the trial should be stopped. Interim analyses will be performed after the first 400 patients are enrolled and at predetermined periodic intervals thereafter, until a possible maximum of 2,000 patients are enrolled. These interval analyses will determine when the trial has achieved its endpoints and if AGA Medical is able to conclude the trial prior to enrolling 2,000 patients.

The trial design includes a feasibility phase to be followed by a pivotal phase. The results of the feasibility phase, which consists of the first 30 patients to receive the ACP, will serve to further validate safety conclusions demonstrated through preclinical testing. These patients will be followed for 45 days after the procedure and evaluated for adverse events. The 45-day feasibility data will be reviewed by an independent data safety monitoring board prior to FDA review. Additional subjects will be enrolled in the pivotal phase of the trial after the FDA has completed its review.

Scientific data have demonstrated that patients with atrial fibrillation face a five-fold higher incidence of stroke. Clinical research has further demonstrated that a stroke in these patients is linked to the LAA, a small structure, shaped like a pouch, off the left atrium. Atrial fibrillation can cause blood to pool in the LAA, increasing the chance of clots that may travel to the brain. The current standard of medical care is to treat these patients with anticoagulants, which are difficult to tolerate for many people and carry a risk of complications, such as bleeding.

The Amplatzer Cardiac Plug received European CE mark approval in December 2008, and is currently sold in Europe, South America and parts of the Pacific Rim.

For more information: www.amplatzer.com

Related Content

Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future.

Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future. Getty Images

News | Cardiovascular Clinical Studies | June 24, 2021
June 24, 2021 — Data captured in American College of Cardiology (ACC)...
Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium.

Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium. 

News | Cardiovascular Clinical Studies | January 27, 2021
January 27, 2021 — A New York Institute of Technology research te
Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...